NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 127 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $571,515 | -69.7% | 152,187 | -59.5% | 0.00% | -69.2% |
| Q4 2022 | $1,888,245 | -49.2% | 376,162 | +32.4% | 0.01% | -50.0% |
| Q3 2022 | $3,716,000 | +33.5% | 284,050 | +30.8% | 0.03% | +13.0% |
| Q2 2022 | $2,784,000 | -15.9% | 217,187 | 0.0% | 0.02% | 0.0% |
| Q1 2022 | $3,312,000 | -72.1% | 217,187 | -61.5% | 0.02% | -71.6% |
| Q3 2021 | $11,856,000 | +6.6% | 564,059 | 0.0% | 0.08% | +6.6% |
| Q2 2021 | $11,123,000 | +72.4% | 564,059 | +154.5% | 0.08% | +40.7% |
| Q1 2021 | $6,450,000 | -3.9% | 221,634 | 0.0% | 0.05% | +1.9% |
| Q4 2020 | $6,715,000 | +84.5% | 221,634 | -3.1% | 0.05% | +55.9% |
| Q3 2020 | $3,639,000 | -19.4% | 228,764 | 0.0% | 0.03% | -29.2% |
| Q2 2020 | $4,516,000 | +3.2% | 228,764 | -5.5% | 0.05% | 0.0% |
| Q1 2020 | $4,374,000 | -2.3% | 242,000 | 0.0% | 0.05% | 0.0% |
| Q4 2019 | $4,475,000 | +108.4% | 242,000 | +56.1% | 0.05% | +71.4% |
| Q3 2019 | $2,147,000 | +9.1% | 155,000 | +14.8% | 0.03% | +12.0% |
| Q2 2019 | $1,968,000 | – | 135,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 18,136,735 | $232,513,000 | 49.48% |
| Ponoi II Management, LLC | 1,298,908 | $16,652,000 | 45.25% |
| Ponoi Management, LLC | 1,298,908 | $16,652,000 | 26.29% |
| Euclidean Capital LLC | 746,674 | $9,572,000 | 8.14% |
| StepStone Group LP | 1,573,357 | $20,170,000 | 2.16% |
| First Light Asset Management, LLC | 1,135,884 | $14,562,000 | 1.69% |
| Lexington Partners L.P. | 110,428 | $1,416,000 | 0.73% |
| Rubric Capital Management LP | 797,588 | $10,225,000 | 0.54% |
| Boxer Capital, LLC | 500,000 | $6,410,000 | 0.41% |
| DAFNA Capital Management LLC | 107,653 | $1,380,000 | 0.38% |